Industry
Medical - Devices
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Loading...
Open
1.16
Mkt cap
36M
Volume
128K
High
1.18
P/E Ratio
-0.90
52-wk high
2.23
Low
1.14
Div yield
N/A
52-wk low
1.00
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 1:36 pm
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 1:33 pm
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 1:32 pm
Portfolio Pulse from Benzinga Newsdesk
September 05, 2024 | 1:32 pm
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 4:43 pm
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 3:35 pm
Portfolio Pulse from Benzinga Newsdesk
August 19, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 5:55 pm
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 6:19 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 8:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.